Akoya Biosciences (AKYA) announced a collaboration with the Singapore Translational Cancer Consortium on the STCC Unified PD1/PDL1 Evaluation of Response study. This initiative aims to identify and validate key biomarkers predicting response or refractoriness to immune checkpoint inhibitors using Akoya’s IO60 panel for spatial proteomic analysis. While PD-1/PD-L1 inhibitors have revolutionized cancer treatment, patient responses vary widely. The SUPER study is the first study in Singapore, focusing on a unique case-control pan-cancer cohort of 200 patients -100 exceptional responders matched with 100 hyperprogressors to immune checkpoint inhibitors – which seeks to uncover the biological determinants of varied treatment outcomes. The SUPER Study will leverage Akoya’s IO60 panel, with other multiomic profiling modalities, to enhance biomarker-driven cancer treatment and improve patient outcomes. Key Objectives of the Study: To identify and validate the assay combination and biomarker profile that best predicts response or refractoriness to PD1/PDL1 inhibition. Develop a combinatorial assay kit/model that best predicts PD1/PDL1 treatment response for clinical applications. Establish a national biomarker discovery program for extreme responders – individuals that have an exceptionally favorable or unusually poor response to cancer treatment. As part of the collaboration, Akoya’s IO60 panel will be used to analyze the tumor microenvironment, providing insights into immune cell interactions and biomarker expression patterns in this matched cohort of patients. The study’s findings could have significant implications for future cancer immunotherapy approaches and healthcare cost optimization.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- Akoya Biosciences price target lowered to $1.65 from $2.40 at Piper Sandler
- Akoya Biosciences, Team SAMBAI announce selection of PhenoCycler-Fusion
- Tikvah intends to vote against Quanterix’s proposed merger with Akoya
- Akoya Biosciences downgraded to Equal Weight from Overweight at Stephens
- Cautious Outlook on Akoya Biosciences Amid Acquisition Uncertainties and Mixed Financial Performance